Search Results - "Bizzari, J P"

Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UK by O'Brien, M. E. R., Leonard, R. C., Barrett-Lee, P. J., Eggleton, S. P. H., Bizzari, J.-P.

“…Background: Given as first- or second-line chemotherapy, docetaxel appears to have great potential in advanced breast cancer. Patients and methods: Three…”
Get full text

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma by Gerard, B, Aamdal, S, Lee, S M, Leyvraz, S, Lucas, C, D'Incalci, M, Bizzari, J P

“…We report the results and discuss the toxicity of clinical trials based on a single concept: the decrease in O6alkyl DNA alkyltransferase (O6AT) resistance…”
Get more information

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil by JULIA, A.-M, ROCHE, H, BERLION, M, LUCAS, C, MILANO, G, ROBERT, J, BIZZARI, J.-P, CANAL, P

“…The current work was undertaken to investigate the importance of exposure sequence and duration in achieving the maximum reversal action of S9788 on…”
Get full text

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer by Pujol, J L, Monnier, A, Berille, J, Cerrina, M L, Douillard, J Y, Rivière, A, Grandgirard, A, Gouva, S, Bizzari, J P, Le Chevalier, T

“…A phase II study was designed to evaluate objective response rate and toxicity of fotemustine as single-drug chemotherapy in non-small-cell lung cancer…”
Get full text

Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance by Léonce, S, Pierré, A, Anstett, M, Pérez, V, Genton, A, Bizzari, J P, Atassi, G

“…A new triazinoaminopiperidine derivative, Servier 9788 (S9788), was investigated for its ability to increase Adriamycin (ADR) accumulation and retention in two…”
Get more information

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer by Le Chevalier, T, Bérille, J, Zalcberg, J R, Millward, M J, Monnier, A, Douillard, J Y, McKeage, M J, James, R, Soulas, F, Loret, C, Bougon, N, Bizzari, J P

“…Cisplatin-based chemotherapy is effective in non-small cell lung cancer (NSCLC), although it prolongs survival only modestly. Single-agent docetaxel (Taxotere;…”
Get more information

Follow up of soluble IL‐2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy by SOUBRANE, CL, MOUAWAD, R., ICHEN, M., SUISSA, J., BOREL, CH, VUILLEMIN, E., BENHAMMOUDA, A., BIZZARI, J. P., WEIL, M., KHAYAT, D.

“…SUMMARY Immunological parameters following chemoimmunotherapy combination were studied in 31 patients with metastatic malignant melanoina. They received…”
Get full text

Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma by Richard, M A, Grob, J J, Zarrour, H, Bassères, N, Bizzari, J P, Gérard, B, Bonerandi, J J

“…The combination of dacarbazine (DTIC), cisplatin (DDP), carmustine and tamoxifen (TAM) has been reported to yield a high rate of response in patients with…”
Get more information

Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule by KHAYAT, D, LOKIEC, F, BIZZARI, J.-P, WEIL, M, MEEUS, L, SELLAMI, M, ROUESSE, J, BANZET, P, JACQUILLAT, C

“…Diethyl-1-[3-(2-chloroethyl)-3-nitrosoureido]ethylphosphonate (S 10036) is a new nitrosourea that has been evaluated in a clinical trial because of its…”
Get full text

Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma by Khayat, D, Bizzari, J P, Frenay, M, Naman, H, Weil, M, Goupil, A, Namer, M, Rouesse, J, Banzet, P, Jacquillat, C

“…Thirty-three patients with disseminated malignant melanoma were entered in a phase II study of the new nitrosourea S 10036 using a 100-mg/m2 weekly induction…”
Get more information

In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea by FISCHEL, J. L, FORMENTO, P, ETIENNE, M. C, GIOANNI, J, FRENAY, M, DELOFFRE, P, BIZZARI, J. P, MILANO, G

“…Fotemustine (S 10036) is a new anti-tumor nitrosourea characterized by a phosphonoalanine carrier group coupled to the nitrosourea moiety, which potentially…”
Get full text

Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients by Rixe, O, Borel, C, Paraiso, D, Benhammouda, A, Petit, T, Antoine, E, Bizzari, J P, Auclerc, G, Soubrane, C, Weil, M

“…Fotemustine and dacarbazine constitute the most active single chemotherapeutic agents in the treatment of melanoma. In this phase II study we evaluated the…”
Get more information

Characterization of the pharmacological antitumor effects of S 12363, a new vinca alkaloid by Atassi, G, Berlion, M, el Oche, Y, Bizzari, J P

“…S 12363 is a new highly potent vinca alkaloid derivative characterized by the grafting of an a-aminophosphonate, bioisoster of the valine, at the C23 position…”
Get more information

The estimation of self-renewal in the clonogenic cells of human solid tumours: A comparison of secondary plating efficiency and colony size by BIZZARI, J. P, MACKILLOP, W. J

“…The in vitro clonogenicity of 25 human tumours was compared in two simple two layer culture systems, agar/agar and liquid medium/agar. There was a strong…”
Get full text

Fotemustine: an overview of its clinical activity in disseminated malignant melanoma by Khayat, D, Avril, M F, Gerard, B, Bertrand, P, Bizzari, J P, Cour, V

“…Fotemustine is a new chloronitrosourea which is active against disseminated malignant melanoma (DMM), and especially against cerebral metastases (CM). This…”
Get more information

Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study by Khayat, D, Cour, V, Bizzari, J P, Aigner, K, Borel, C, Cohen-Alloro, G, Weil, M, Auclerc, G, Buthiau, D, Bousquet, J C

“…Fotemustine is a new nitrosourea which has shown some efficacy on disseminated malignant melanoma (DMM) (24.2% response rate (RR) among 153 patients in a Phase…”
Get more information

Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines by Fischel, J L, Barbé, V, Berlion, M, Formento, P, Berrile, J, Bizzari, J P, Milano, G

“…Fotemustine (Fote) is a new amino acid-linked chloroethyl nitrosourea which has been shown to be useful in disseminated malignant melanoma. The aim of the…”
Get more information

Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid by FISCHEL, J. L, FORMENTO, P, BERLION, M, GIOANNI, J, BIZZARI, J. P, MILANO, G

“…The present study was designed to analyse the cytotoxic effects of the combination of fotemustine with 5-fluorouracil (5-FU) plus folinic acid (FA). Two human…”
Get full text

Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine by Oliver, V, Aliaga, A, Lopez Lopez, J J, Perez, E, Ponchon, A, Bizzari, J P, Cour, V

Get more information

Evaluation of the time-schedule dependency for the cytotoxic activity of the new vinca alkaloid derivative, S 12363 (vinfosiltine) by Fischel, J L, Berlion, M, Formento, P, Bizzari, J P, Milano, G

“…S 12363 is a new vinca alkaloid derivative obtained by appending an optically active alpha-aminophosphonate at the C23 position of 04-deacetyl vinblastine. The…”
Get more information